Effects of the 340B Drug Pricing Program on medication use and health in Medicare patients
Official title: Impact of the 340B Drug Pricing Program on Medication Utilization, Health Outcomes, and Disparities in Medicare
Funded at New York University School of Medicine · NIH-11047418 · Data updated 2026-11-12
This study looks at how the 340B Drug Pricing Program helps Medicare patients, especially those who are struggling financially, by checking if it really makes it easier for them to get affordable medications and stay healthy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | November 15, 2024 |
| Project end | October 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $674,227 |
| NIH project number | 1R01AG086300-01A1 |
| Project ID | NIH-11047418 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include Medicare patients, especially those from low-income or underserved populations who may be affected by medication access issues.
✕Less likely to help
Patients who are not enrolled in Medicare or those who do not have access to the 340B Drug Pricing Program may not benefit from this research.
What this research studies
This research investigates how the 340B Drug Pricing Program affects medication access and health outcomes for Medicare patients, particularly those from disadvantaged backgrounds. It examines whether the program's intended benefits, such as increased access to affordable medications, are being realized and how they impact patient health. The study will analyze medication utilization patterns and health outcomes to determine if the program is meeting its goals or if it inadvertently leads to inappropriate prescribing practices. By focusing on both infused and pharmacy-dispensed drugs, the research aims to provide a comprehensive understanding of the program's effectiveness.
Why it matters
Potential benefit: If successful, this research could lead to improved medication access and health outcomes for Medicare patients, particularly those in disadvantaged communities.
How similar studies have gone: Previous research on the 340B Drug Pricing Program has shown mixed results, indicating that while some benefits exist, there is a need for further investigation into its overall impact on patient health outcomes.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Desai, Sunita — New York University School of Medicine
- Study coordinator: Desai, Sunita
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.